Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTX958 in Active Psoriatic Arthritis
NCT05715125Phase 2Terminated
- Sponsor
- Ventyx Biosciences
- Start
- Jan 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of cenacitinib in psoriatic arthritis (PsA) (3 arms), sponsored by Ventyx Biosciences. Primary endpoints: Proportion of participants achieving 20% improvement in American College of Rheumatology criteria at 16 weeks and Incidence of Treatment Emergent Adverse Events at 16 weeks. Started Jan 2023; status: terminated.
02
Drugs
cenacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05715125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05715125.